GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (XCNQ:DRUG) » Definitions » 6-1 Month Momentum %

Bright Minds Biosciences (XCNQ:DRUG) 6-1 Month Momentum % : 4025.87% (As of Dec. 14, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-12-14), Bright Minds Biosciences's 6-1 Month Momentum % is 4025.87%.

The industry rank for Bright Minds Biosciences's 6-1 Month Momentum % or its related term are showing as below:

XCNQ:DRUG's 6-1 Month Momentum % is ranked better than
99.86% of 1473 companies
in the Biotechnology industry
Industry Median: -9.53 vs XCNQ:DRUG: 4025.87

Competitive Comparison of Bright Minds Biosciences's 6-1 Month Momentum %

For the Biotechnology subindustry, Bright Minds Biosciences's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bright Minds Biosciences's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bright Minds Biosciences's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Bright Minds Biosciences's 6-1 Month Momentum % falls into.



Bright Minds Biosciences  (XCNQ:DRUG) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bright Minds Biosciences  (XCNQ:DRUG) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Bright Minds Biosciences 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Bright Minds Biosciences's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bright Minds Biosciences Business Description

Traded in Other Exchanges
Address
19 Vestry Street, New York, NY, USA, 10013
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Executives
Ryan Cheung Senior Officer
Nils Bottler Director
Jeremy Fryzuk Director
Alan Kozikowski 10% Security Holder, Director, Senior Officer
Ian Mcdonald Director